Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain

Supportive Care in Cancer

Volumn 20, Issue 3, 2012, Pages 565-573

  Radbruch, Lukas ^a   Torres, Luis M ^b   Ellershaw, John E ^c   Gatti, Antonio ^d   Luis Lerzo, Guillermo ^e   Revnic, Julia ^f   Taylor, Donald ^g  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c Marie Curie Palliative Care Institute   (United Kingdom)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e Investigaciones Medicas Buenos Aires   (Argentina)

^f HÔTEL DIEU   (France)

^g Taylor Research LLC ^*  (United States)

Author keywords

Breakthrough pain; Cancer; Fentanyl; Intranasal; Patient acceptability

Indexed keywords

FENTANYL; NOSE SPRAY;

ADULT; ARTICLE; BREAKTHROUGH PAIN; BURNING SENSATION; CANCER PAIN; CONSTIPATION; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; DYSPNEA; EPISTAXIS; FEMALE; HUMAN; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MULTICENTER STUDY; NASAL PRURITUS; NAUSEA; NOSE OBSTRUCTION; PATIENT SATISFACTION; PRIORITY JOURNAL; RHINORRHEA; SORE THROAT; TASTE DISORDER; TREATMENT OUTCOME; URTICARIA;

ABSORPTION; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MORPHINE; NASAL MUCOSA; NASAL SPRAYS; NEOPLASMS; PAIN MEASUREMENT; PATIENT SATISFACTION; PECTINS;

EID: 84857658446     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1124-x     Document Type: Article

References (21)

1. DS Bennett AW Burton S Fishman, et al. 2005 Consensus panel recommendations for the assessment and management of breakthrough pain, part 2: management Pharm Ther 30 6 354 361 (Pubitemid 40885216)
2. F Brennan 2007 Palliative care as an international human right J Pain Symptom Manage 33 5 494 499 17482036 10.1016/j.jpainsymman.2007.02.022 (Pubitemid 46669893)
3. A Caraceni C Martini E Zecca, et al. 2004 Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey Palliat Med 18 3 177 183 15198130 10.1191/0269216304pm890oa (Pubitemid 38771657)
4. NI Cherny J Baselga F de Conno L Radbruch 2010 Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative Ann Oncol 21 3 615 626 20176694 10.1093/annonc/mdp581 1:STN:280:DC%2BC3c7ivVGitA%3D%3D
5. SL Collins CC Faura RA Moore HJ McQuay 1998 Peak plasma concentrations after oral morphine: a systematic review J Pain Symptom Manage 16 6 388 402 9879164 10.1016/S0885-3924(98)00094-3 1:STN:280:DyaK1M%2FpsFagtQ%3D%3D (Pubitemid 29006202)
6. O Dale R Hjortkjaer ED Kharasch 2002 Nasal administration of opioids for pain management in adults Acta Anaesthesiol Scand 46 7 759 770 12139528 10.1034/j.1399-6576.2002.460702.x 1:STN:280:DC%2BD38vktFSlug%3D%3D (Pubitemid 34803193)
7. AN Davies K Broadley D Beighton 2001 Xerostomia in patients with advanced cancer J Pain Symptom Manage 22 4 820 825 11576798 10.1016/S0885-3924(01)00318- 9 1:STN:280:DC%2BD3MrjtVGjug%3D%3D (Pubitemid 32884374)
8. AN Davies A Dickman C Reid AM Stevens G Zeppetella 2009 The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain 13 4 331 338 18707904 10.1016/j.ejpain.2008.06.014
9. AN Davies J Vriens A Kennett M McTaggart 2008 An observational study of oncology patients' utilization of breakthrough pain medication J Pain Symptom Manage 35 4 406 411 18222631 10.1016/j.jpainsymman.2007.05.010
10. M Fallon A Gatti AN Davies, et al. 2009 Efficacy, safety and patient acceptability of fentanyl pectin nasal spray compared with immediate-release morphine sulphate tablets in the treatment of breakthrough cancer pain: a multicentre, double-blind, double-dummy, multiple-crossover study Eur J Cancer Supp 7 15 10.1016/S1359-6349(09)72064-6
11. L Illum 2003 Nasal drug delivery-possibilities, problems and solutions J Control Release 87 1-3 187 198 12618035 10.1016/S0168-3659(02)00363-2 1:CAS:528:DC%2BD3sXhsFOls7c%3D (Pubitemid 36255456)
12. S Mercadante L Radbruch A Caraceni, et al. 2002 Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care Cancer 94 3 832 839 11857319 10.1002/cncr.10249 (Pubitemid 34132314)
13. C Miaskowski MJ Dodd C West, et al. 2001 Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management J Clin Oncol 19 23 4275 4279 11731509 1:STN:280:DC%2BD3MnosFWgtw%3D%3D (Pubitemid 33096774)
14. F Petzke L Radbruch D Zech G Loick S Grond 1999 Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic J Pain Symptom Manage 17 6 391 401 10388244 10.1016/S0885-3924(99)00023-8 1:STN:280:DyaK1MzhsVaquw%3D%3D (Pubitemid 29289765)
15. R Portenoy D Bruns B Shoemaker S Shoemaker 2010 Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics J Opioid Manag 6 97 108 20481174 10.5055/jom.2010.0009
16. RK Portenoy A Burton N Gabrail 2010 A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain Pain 151 3 617 624 20800358 10.1016/j.pain.2010.07.028 1:CAS:528:DC%2BC3cXhtlKmsrzF
17. RK Portenoy NA Hagen 1990 Breakthrough pain: definition, prevalence and characteristics Pain 41 3 273 281 1697056 10.1016/0304-3959(90)90004-W 1:STN:280:DyaK3czls1aktw%3D%3D (Pubitemid 20187930)
18. RK Portenoy D Payne P Jacobsen 1999 Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1-2 129 134 10353500 10.1016/S0304-3959(99)00006-8 1:STN:280:DyaK1M3nvF2nsg%3D%3D (Pubitemid 29199908)
19. KB Svendsen S Andersen S Arnason, et al. 2005 Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms Eur J Pain 9 2 195 206 15737812 10.1016/j.ejpain.2004.06.001 (Pubitemid 40311842)
20. G Walker A Wilcock C Manderson R Weller V Crosby 2003 The acceptability of different routes of administration of analgesia for breakthrough pain Palliat Med 17 2 219 221 12701855 10.1191/0269216303pm755oa 1:STN:280: DC%2BD3s7ot1OhtQ%3D%3D (Pubitemid 36432601)
21. P Watts A Smith 2009 PecSys: in situ gelling system for optimised nasal drug delivery Expert Opin Drug Deliv 6 5 543 552 19413461 10.1517/ 17425240902939135 1:CAS:528:DC%2BD1MXltlOjurY%3D